TLDR
- UTHR pops 8.15% to $512 as 2025 revenue hits a record $3.18B.
- Tyvaso surges to $1.88B in 2025, led by fast-growing Tyvaso DPI uptake.
- Q4 revenue rises 7% to $790M as PAH demand stays strong across key drugs.
- 2025 net income hits $1.33B; EPS climbs to $27.86 on firm margins.
- R&D climbs to $550M as organ manufacturing and device programs accelerate.
United Therapeutics (UTHR) shares advanced sharply after the company posted record 2025 revenue and stronger product expansion. The stock moved to $512.02 after an 8.15% gain as the market reacted to rising full-year performance. The momentum built as the firm delivered higher earnings, continued portfolio growth, and broader commercial execution.
United Therapeutics Corporation, UTHR
Record Revenue Strength and Expanding Product Performance
United Therapeutics reported full-year revenue of $3.18 billion, marking 11 percent growth from 2024. The company reached a new performance milestone as product sales rose across several core therapies. Continued expansion in patient access supported the rise in annual revenue.
The firm recorded fourth-quarter revenue of $790.2 million, representing a 7% increase. Consistent demand across key pulmonary arterial hypertension medicines drove the improvement. Product diversification continued to support higher year-end totals.
Net income reached $1.33 billion for 2025, reflecting a sustained rise in operating strength. Earnings per diluted share climbed to $27.86 as margins held firm. Disciplined cost management contributed meaningfully to the overall performance.
Breakout Tyvaso Growth Drives Operational Momentum
Tyvaso products delivered major gains and strengthened the company’s respiratory portfolio. Total Tyvaso revenue rose to $1.88 billion for 2025, supported by increased Tyvaso DPI use. The DPI format showed rapid patient adoption and higher utilization following Medicare Part D adjustments.
Fourth-quarter Tyvaso revenue reached $464.3 million, showing growth from rising quantities sold. Broader clinical adoption also supported momentum for the DPI platform. The firm expanded commercial reach in a market facing rising treatment demand.
Orenitram delivered steady gains with 2025 revenue of $496.9 million. Increased prescription growth aligned with wider commercial engagement and stronger therapy positioning. Rising utilization supported continued expansion during the year.
Operational Costs, R&D Investment, and Strategic Actions
Total cost of sales rose as production, royalties, and inventory reserves increased. The company also expanded output to support its broader product mix. Regulatory production requirements continued to add pressure on manufacturing spending.
Research and development costs increased to $550 million for 2025. The company advanced organ manufacturing programs and device development projects during the year. Internal research expenses grew as clinical activity expanded.
Selling, general, and administrative expenses reached $755.8 million. The rise reflected higher personnel costs and marketing expansion across therapeutic categories. The firm recorded reduced litigation expenses after prior accruals
Considering a new stock? You may want to see what’s on our watchlist first.
Our team at Knockout Stocks follows top-performing analysts and market-moving trends to spot potential winners early. We’ve identified five stocks gaining quiet attention that could be worth watching now. Create your free account to unlock the full report and get ongoing stock insights.Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
